Barclays PLC Aerovate Therapeutics, Inc. Transaction History
Barclays PLC
- $288 Billion
- Q1 2024
A detailed history of Barclays PLC transactions in Aerovate Therapeutics, Inc. stock. As of the latest transaction made, Barclays PLC holds 7,872 shares of AVTE stock, worth $137,366. This represents 0.0% of its overall portfolio holdings.
Number of Shares
7,872
Previous 15,394
48.86%
Holding current value
$137,366
Previous $348,000
33.05%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding AVTE
# of Institutions
81Shares Held
20.3MCall Options Held
0Put Options Held
0-
Sofinnova Investments, Inc. Menlo Park, CA3.76MShares$65.6 Million6.47% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA2.2MShares$38.4 Million6.85% of portfolio
-
Atlas Venture Life Science Advisors, LLC2.04MShares$35.6 Million7.55% of portfolio
-
Baker Bros. Advisors LP New York, NY1.68MShares$29.3 Million0.63% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA1.2MShares$21 Million1.87% of portfolio
About Aerovate Therapeutics, Inc.
- Ticker AVTE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 24,448,100
- Market Cap $427M
- Description
- Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which ...